Indeterminate results of the second-generation hepatitis C virus (HCV) recombinant immunoblot assay: significance of high-level c22-3 reactivity and influence of HCV genotypes
Zein, N.N.; Germer, J.J.; Wendt, N.K.; Schimek, C.M.; Thorvilson, J.N.; Mitchell, P.S.; Persing, D.H.
Journal of Clinical Microbiology 35(1): 311-312
A second-generation recombinant immunoblot assay (RIBA 2.0) is used in the United States to confirm infection with hepatitis C virus (HCV) in samples that are anti-HCV (enzyme immunoassay) positive. In some cases, indeterminate results of RIBA 2.0, which are defined as reactivity to a single antigen species or reactivity limited to two proteins derived from the same coding region of the HCV genome, are encountered.